Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated Patients
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- Immedica Pharma US Inc
- Study ID
- NCT07573059
- Status
- Recruiting
Conditions
- ARG1 Deficiency
Eligibility Criteria
- Sex
- ALL
- Age
- 0 Years - 100 Years
- Healthy Volunteers
- Not accepted
Interventions
- Loargys Arginine Test System — DEVICELoargys Arginine Test System
Study Details
Arginase 1 deficiency (ARG1-D) is a rare condition in which the body cannot properly break down a substance called arginine. This leads to high levels of arginine and related substances in the blood, which can cause serious health problems and reduce quality of life. Loargys is a new treatment designed to lower arginine levels in people with ARG1-D. It works by providing a modified version of a natural enzyme that breaks down arginine in the blood. The dose of Loargys is adjusted for each patient based on their arginine levels. Because Loargys continues to break down arginine even after a blood sample has been taken, to ensure accurate results, a special substance (called nor-NOHA) is added to the blood collection tubes to stop this process after the sample is taken. The arginine levels are then measured using a standard laboratory test. The Loargys Arginine Test System used in this study includes both the special blood collection tubes and the laboratory test used to measure arginine. The purpose of this study is to evaluate the safety of this test system when used to measure arginine levels in patients receiving Loargys.
Key Dates
- Start date
- Apr 17, 2026
- Status verified
- May 2026
- Primary completion
- Jul 15, 2027
- Completion
- Jul 15, 2027
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Other: Loargys Arginine Test System
Primary Outcome Measure
Incidence of AEs related to the Loargys Arginine Test System [ Time Frame: Through study completion, up to 21 months ]
Central Contacts
- Head of Global Integrated Evidence Generation+46(0)853339500
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Rare Disease Research | Atlanta | Georgia | 303029 |